Abstract

SV2A LIGAND AS THERAPY OF EPILEPSY

Lindae Novianae, M. Farm Klin., Apt* and Drs. Sumarno, Sp. FRS., Apt.

Abstract

Epilepsy describes a condition where a person has recurrent seizures risks due to a chronic process as the initial cause. A seizure is a transient occurrence of signs or symptoms due to excessive neuronal activity in the brain. A seizure is a result of an unbalance of excitation and inhibition within the CNS. The ILAE has released a 2017 version of seizure-type classification, basic and expanded version. Seizure classification is significant in designing the treatment plan because some epileptic medicines have different activities against various seizure types. Antiepileptic medicines acts primarily by blocking the initiation or spread of seizures through a variety of mechanisms. The newer mechanism of antiepileptic medicines is binding to the glycoprotein SV2A. This paper discussed SV2A ligand (levetiracetam and brivaracetam) for the treatment of epilepsy. The discussion included aspect of pharmacology, some clinical studies about efficacy, safety, and tolerability, so it could provide information related to the new SV2A ligand medicines in determining medicine choices for the treatment of epilepsy.

Keywords: Epilepsy, brivaracetam, levetiracetam, seizure, SV2A ligands.